Fig. S2 from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing <i>NOTCH1</i> Expression and Targeting Tumor-Initiating Cells

Sarmishtha De,Daniel J. Lindner,Claire J. Coleman,Gary Wildey,Afshin Dowlati,George R. Stark

crossref（2023）

Cited 37|Views6

No score

Abstract

Supplementary Fig S2. SCLC TICs are enriched for stem cell markers. A, B, C, Expression levels of SOX2, NANOG and OCT4 mRNAs in CD133high and CD133low H82 (A) and H526 (B) cells or CD44high and CD44low H446 (C) cells. D, Levels of SOX2 and OCT4, determined by Western analysis in CD133high and CD133low H82 and H526 cells or CD44high and CD44low H446 cells.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined

Fig. S2 from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing &lt;i&gt;NOTCH1&lt;/i&gt; Expression and Targeting Tumor-Initiating Cells

Fig. S2 from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing <i>NOTCH1</i> Expression and Targeting Tumor-Initiating Cells